Abstract 13P
Background
Breast cancer (BC) is the third most common cancer in the world and is the most common cancer in Iran in both sexes. Worldwide, there will be about 2.1 million newly diagnosed female breast cancer cases in 2018, accounting for almost 1 in 4 cancer cases among women. The aim of this study was to provide recent data on the BC incidence and distribution in East Azerbaijan, Iran.
Methods
East Azerbaijan is the largest and most populous province in the northwest of Iran, which more than 95% of the population is of Azeri ethnicity. Data of the patients diagnosed with confirmed BC as registered in the East Azerbaijan population based cancer registry between 2015 and 2017, were linked to the main data sources. The age standardized incidence rates (ASIRs) for BC were estimated.
Results
We had overall 1410 primary breast cancer cases during two years, in both sexes, which accounted 10.3% of cancer cases. The mean age of our patients was 51.07(±13.29), with the age range of 21 to 99 years old. About 98.2% of BC was female, and 1.7% of them were male. The most common morphology was ductal carcinoma (n = 1077, 76.4%), and most of our BC patient were in grade II of disease (35.9%). In 31.2% of patients had lymphatic Invasion, 17.8 % vascular invasion, and 8.7% of them had neural invasion. Also, our results showed that breast cancer was the most common cancer among female, with slightly increasing of ASRs from 31.1 to 31.7 per 100,000 women during 2 years. There were two age peaks of ASRs in women, first in approximately 45-55 years and second in 60-70 years old groups.
Conclusions
We observed slightly increase in incidence of BC, which might be explained by the improvement of compliance to the cancer registration, compared with previous reports of our region. However, the low tumor stages and improved knowledge and attitude of women to early diagnosis and screening, which we have recently addressed in our ongoing screening programs in the province, may have played important roles in these results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract